Abstract: Early diagnosis and treatment are crucial for improving the cure rate and survival rate of patients with malignant tumors. In recent years, the development of multimodal molecular imaging has provided new directions for the early diagnosis and treatment of malignant tumors. Nuclear medicine imaging has the advantages of high sensitivity, high tissue penetration, and precise quantification, which can play an important role in disease diagnosis and monitoring. Combining it with CT, MRI, optical imaging and other imaging modalities, can provide more comprehensive anatomical and biometabolic information for the diagnosis and treatment of tumors. Currently, the construction of radionuclide-labelled multimodal probes based on nanomedicine strategies has received widespread attention. The authors review the research progress on radionuclide-labelled nanoprobes in multimodal imaging of tumors based on relevant preclinical research results at home and abroad.